Article Text

Download PDFPDF

Extending the clinical and mutational spectrum of TRIM32-related myopathies in a non-Hutterite population
  1. Katherine Johnson1,
  2. Willem De Ridder2,3,4,
  3. Ana Töpf1,
  4. Marta Bertoli1,
  5. Lauren Phillips1,
  6. Peter De Jonghe2,3,4,
  7. Jonathan Baets2,3,4,
  8. Tine Deconinck2,3,
  9. Vidosava Rakocevic Stojanovic5,
  10. Stojan Perić5,
  11. Hacer Durmus6,
  12. Shirin Jamal-Omidi7,
  13. Shahriar Nafissi7,
  14. Tiziana Mongini8,
  15. Anna Łusakowska9,
  16. Mark Busby10,
  17. James Miller11,
  18. Fiona Norwood12,
  19. Judith Hudson13,
  20. Rita Barresi1,14,
  21. Monkol Lek15,16,
  22. Daniel G MacArthur15,16,
  23. Volker Straub1
  1. 1 John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
  2. 2 Neurogenetics Group, Center for Molecular Neurology, VIB, Antwerp, Belgium
  3. 3 Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium
  4. 4 Neuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, Antwerp, Belgium
  5. 5 Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia
  6. 6 Department of Neurology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
  7. 7 Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran
  8. 8 Department of Neurosciences ‘Rita Levi Montalcini’, University of Turin, Turin, Italy
  9. 9 Department of Neurology, Medical University of Warsaw, Warsaw, Poland
  10. 10 Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK
  11. 11 The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
  12. 12 King’s College Hospital, London, UK
  13. 13 Northern Molecular Genetics Service, Biomedicine East Wing, Newcastle upon Tyne, UK
  14. 14 Muscle Immunoanalysis Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
  15. 15 Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, USA
  16. 16 Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA
  1. Correspondence to Professor Volker Straub, The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle upon Tyne, NE1 3BZ, UK; volker.straub{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


TRIM32-related myopathies represent a phenotypic spectrum of a rare autosomal recessive muscle disorder. The disease is described as a mild and progressive myopathy without characteristic clinical features. Originally classified as limb-girdle muscular dystrophy (LGMD) 2H (OMIM #254110), the disorder was first identified in the Hutterite population and the homozygous TRIM32 founder mutation, p.Asp487Asn, was identified as the cause of this disease.1 Only seven patients with definite non-Hutterite TRIM32-related myopathy have been reported in the literature. Apart from two missense mutations residing in the NHL repeats of TRIM32, only deletions, frameshift and nonsense mutations have been reported.2 Having applied next generation sequencing technologies to over 1000 patients with suspected genetic muscle disorders, we present nine patients with TRIM32-related myopathies and three patients with a homozygous TRIM32 variant of unknown significance (VUS).

Subjects and methods

DNA samples from 1000 patients with unexplained limb-girdle muscle weakness and/or elevated serum creatine kinase (CK) levels were gathered through the MYO-SEQ project. Samples were processed and whole exome sequencing (WES) performed as described previously.3 Additional patients with TRIM32-related myopathy were diagnosed by the Northern Molecular Genetics Service (NMGS) diagnostic laboratory through panel sequencing of 32 LGMD genes. Variants were classified according to ACMG guidelines.4 MRI imaging was performed for eight patients on a 1.5T MRI platform. Muscle biopsies for all patients were analysed following standard histological techniques.


Genetic findings

Of the 1000 MYO-SEQ patients, we identified 36 with rare coding variants in TRIM32 (minor allele frequency <1%; numbered 1–36 in online supplementary table 1). Twenty-six patients had single heterozygous variants; these were discarded from our analysis as the variants were unlikely to be pathogenic in this autosomal recessive disease. Two further patients were excluded from our analysis: patient 18 was heterozygous for a pathogenic DES mutation and patient 10 was homozygous for a pathogenic CAPN3 mutation. This resulted in seven patients with suspected pathogenic TRIM32 variants and one patient with a homozygous VUS. We included four additional patients harbouring homozygous rare TRIM32 variants: three from NMGS and one for whom WES was performed in Tehran. Two patients harboured a pathogenic variant and two had a VUS. Pathogenic variants outside the NHL repeats were frameshift mutations (online supplementary figure 1); missense mutations in the coiled-coil region and intervening region were classified as a VUS.4

Supplemental material

Supplemental material

Clinical phenotypes

The clinical findings of patients with pathogenic TRIM32 variants are described in the upper panel of online supplementary table 2. The main presenting symptoms were related to proximal lower limb weakness. Axial, facial and periscapular muscles were variably involved. Serum CK levels were moderately increased (≤2000 U/L). Forced vital capacity was normal in the eight patients for whom we had reliable spirometry. There were no patients with a cardiomyopathy. A few striking clinical features were noted for the patients carrying a homozygous TRIM32 VUS (lower panel of online supplementary table 2), including marked distal upper limb weakness for patient 16 and childhood onset and high CK for patient 38.

Supplemental material

Muscle imaging

MRI scans of the patients with pathogenic TRIM32 variants revealed a preferential affection of the posterior thigh compartment, evolving to a diffuse involvement of the anterior thigh in later stages (figure 1). A consistent involvement of the posterior lower leg compartment and the tibialis anterior muscle was observed as well as the peronei muscles in later stages. There was a relative sparing of the flexor hallucis longus, flexor digitorum longus and tibialis posterior muscles. MRI images for the patients carrying a homozygous VUS did not reveal any consistent pattern (online supplementary figure 2).

Supplemental material

Figure 1

T1-weighted axial MRI of the lower limbs of five patients identified with pathogenic TRIM32 variants. MRI images at mid-thigh level on the left and mid-calf level on the right for: (A) patient 14 at approximately 14 years of disease duration; (B) patient 15 at 18 years of disease duration; (C) patient 27 at 8 years of disease duration; (D) patient 28 at 28 years of disease duration; (E) patient 37 at 5 years disease duration. (A–C and E) MRI images at thigh level, with slight differences in the exact level of acquisition of the image, revealed a preferential involvement of posterior compartment muscles. (D) End-stage involvement of all thigh muscles was observed for patient 28. (A–E) MRI images at calf level revealed a similar pattern for all patients, with predominant involvement of the posterior compartment. White arrows indicate relatively spared muscles. FDL, flexor digitorum longus; FHL, flexor hallucis longus; TP, tibialis posterior.

Histological features

Muscle biopsies showed non-specific myopathic or dystrophic changes. Vacuoles containing basophilic material were noted in scattered muscle fibres of patients 14, 15 and 39 (online supplementary figure 3). No specific histopathological features were noted on the biopsies of patients carrying a homozygous VUS in TRIM32.

Supplemental material


To our knowledge, other studies have never yielded such a large cohort of patients with non-Hutterite TRIM32-related myopathy and thus we present an extended understanding of this rare neuromuscular disorder. The highly conserved NHL domain was the focal region of the pathogenic missense variants in this study, with pathogenic variants outside the NHL repeats being frameshift variants. A caveat to WES is that it is commonly considered to be intractable to copy number variation (CNV) and repeat expansion detection. However, specialised analytical software now permits such analysis. Indeed, a heterozygous 63.5 kb deletion overlapping with p.Arg613Ter was identified in patient 36’s exome using a modified version of PennCNV on a custom Illumina Infinium Array.5 Repeat expansion disorders—including facioscapulohumeral dystrophy, myotonic dystrophy type 1 and 2 and oculopharyngeal muscular dystrophy—were excluded in case of clinical suspicion.

The phenotypes of the patients harbouring novel variants were not strikingly different from those of the patients with known pathogenic variants. Consistent with the current literature, distal upper limb weakness seems to be exceptional while axial, facial and periscapular muscles were variably involved. Despite TRIM32-related myopathy being described as a ‘mild’ myopathy, four patients in our cohort were wheelchair-dependent. Our data do not provide evidence in favour of cardiac or respiratory involvement. MRI imaging revealed a consistent pattern of muscle involvement. The histological features in our patients encompassed the LGMD2H and ‘sarcotubular myopathy’ spectrum that has been described in the literature: non-specific myopathic changes or dystrophic features sometimes accompanied by vacuoles.2

Additionally, we describe the phenotypes of three patients harbouring a homozygous missense TRIM32 VUS. For these patients, no other candidate variants in known myopathy genes were identified. Despite some phenotypic characteristics contrasting with those of the patients with definite pathogenic variants, we cannot exclude that these variants are causal in the disease; future functional data will provide insight into their pathogenicity.

Overall, we report nine patients with TRIM32-related myopathy harbouring 10 pathogenic TRIM32 variants and introduce three patients with a homozygous TRIM32 VUS. Complemented with deep phenotyping, our application of WES enabled patients with TRIM32-related myopathy to be identified. We propose that similar approaches of targeted sequencing and thorough curation of phenotypic information will expedite future TRIM32-related myopathy diagnoses.



  • KJ and WDR contributed equally.

  • Contributors KJ, WDR: study concept and design, acquisition, analysis and interpretation of data, drafting of the manuscript. AT, MB, LP, PdJ, JB, TD, VRS, SP, HD, SJ-O, SN, TM, AŁ, MB, JM, FN, JH, RB, ML, DGM: acquisition, analysis or interpretation of data, critical revision of the manuscript for important intellectual content. VS: study design, revising, design of whole study, acquisition of data, final approval, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

  • Funding This work was supported by Sanofi Genzyme, Ultragenyx, LGMD2I Research Fund, Samantha J Brazzo Foundation, LGMD2D Foundation, Kurt+Peter Foundation, Muscular Dystrophy UK and Coalition to Cure Calpain 3. Diagnostic facilities at the John Walton Muscular Dystrophy Research Centre are supported by the Nationally Commissioned Highly Specialised Service (HSS) for Neuromuscular Diseases (NHS England). This work was also supported by the Association Belge contre les Maladies Neuromusculaire (ABMM) - Aide à la Recherche ASBL. JB is supported by a Senior Clinical Researcher mandate of the Research Fund - Flanders (FWO).

  • Competing interests VS is or has been a principal investigator for trials sponsored by Sanofi Genzyme, GSK, Prosensa/Biomarin, Ionis Pharmaceuticals and Sarepta. He has received speaker honoraria from Sanofi Genzyme. He is or has been on advisory boards for Acceleron Pharma, Audentes Therapeutics, Biomarin, Bristol-Myer Squibb, Italfarmaco S.p.A., Nicox, Pfizer, Sanofi Genzyme, Santhera, Sarepta Therapeutics, Summit Therapeutics, Tivorsan and TrophyNOD. 

  • Patient consent Not required.

  • Ethics approval Ethical approval was granted by the Newcastle and North Tyneside research ethics committee (REC #09/H0906/28) and by the local ethics committees of the participating centres.

  • Provenance and peer review Not commissioned; externally peer reviewed.